


Allen C. Gao, M.D., Ph.D.

Research/Academic Interests	Dr. Gao's research focuses on seeking to better understand the molecular changes associated with the progression of prostate cancer, identification of diagnostic markers and therapeutic targets to stop the progression of late-stage prostate cancer.
Title	Director of Research, Department of Urologic Surgery Professor, Department of Urologic Surgery
Specialty	Cancer
Department	Urologic Surgery
Division	Urology
Center/Program Affiliation	UC Davis Comprehensive Cancer Center
Address/Phone	Research III, Research Building III, 4645 Second Ave Sacramento, CA 95817
Education	M.D., Sichuan Medical College, Chengdu, China 1985 Ph.D., Molecular Biology, University of Texas MD Anderson Cancer Center, Houston TX 1995
Fellowships	Urology and Oncology, Johns Hopkins University, Baltimore MD 1995-1998
Professional Memberships	American Association for Cancer Research American Society of Clinical Oncology American Urological Association European Association of Urology Society of Basic Urologic Research
Honors and Awards	President, Society for Basic Urologic Research (SBUR), 2018, 2019 Senior Research Career Scientist, Department of Veterans Affairs, 2020 Ralph deVere White endowed Professorship in Urologic Oncology Research, UC Davis, 2008
Select Recent Publications	Ning S, Liu C, Lou W, Yang JC, Lombard AP, D'Abronzio LS, Batra N, Yu AM, Leslie AR, Sharifi M, Evans CP, Gao AC. Bioengineered BERA-Wnt5a siRNA targeting Wnt5a/FZD2 signaling suppresses advanced prostate cancer tumor growth and enhances enzalutamide treatment. Mol Cancer Ther. 2022 Aug 5:MCT-22-0216. doi:10.1158/1535-7163. PMID:35930737. Ning S, Zhao J, Lombard AP, D'Abronzio LS, Leslie AR, Sharifi M, Lou W, Liu CF, Yang JC, Evans CP, Corey E, Chen HW, Yu AM, Ghosh PM, Gao AC. Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with



Allen C. Gao, M.D., Ph.D.

patient outcomes. *Commun Med.* 2022 Sep 21;2:118. doi:10.1038/s43856-022-00182-9. PMID: 36159187.


Lombard AP, Armstrong CM, D'Abronzio LS, Ning S, Leslie AR, Sharifi M, Lou W, Evans CP, Dall'Era M, Chen HW, Chen X, Gao AC. Olaparib Induced Senescence is Bypassed through G2/M Checkpoint Override in Olaparib Resistant Prostate Cancer. *Mol Cancer Ther.* 2022 Jan 27: molcanther.0604.2021. doi:10.1158/1535-7163.MCT-21-0604. Online ahead of print. PMID 35086956.

Chengfei Liu, Cameron M. Armstrong, Shu Ning, Joy C. Yang, Wei Lou, Alan P. Lombard, Jing Zhao, Chun-Yi Wu, Aiming Yu, Christopher P. Evans, Clifford G. Tepper, Pui-kai Li, Allen C. Gao. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. *Oncogene.* 2021 Sep;40(35):5379-5392. doi:10.1038/s41388-021-01914-2. Epub 2021 Jul 16. PMID:34272475.

Parikh M, Liu C, Wu CY, Evans CP, Dall'Era M, Robles D, Lara PN, Agarwal N, Gao AC, Pan CX. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. *Sci Rep.* 2021 Mar 18;11(1):6377. doi:10.1038/s41598-021-85969-x. PMID:33737681.

Armstrong CM, Liu C, Liu L, Yang JC, Lou W, Zhao R, Ning S, Lombard AP, Zhao J, D'Abronzio LS, Evans CP, Li PK, Gao AC. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. *Clin Cancer Res.* 2020 Nov 15;26(22):6064-6074. doi:10.1158/1078-0432.CCR-20-1682. Epub 2020 Sep 14. PMID:32928794.

Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. *Nat Commun.* 2018 Nov 16;9(1): 4700. doi:10.1038/s41467-018-07178-x. PMID:30446660.



Allen C. Gao, M.D., Ph.D.

Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. *Mol Cancer Ther*. 2018 Oct;17(10):2197-2205. doi:10.1158/1535-7163.MCT-17-1269. Epub 2018 Jun 11. PMID:29891490.

Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. *Cancer Res*. 2015 Apr 1;75(7):1413-22. doi:10.1158/0008-5472.CAN-14-3080. Epub 2015 Feb 3. PMID:25649766.

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. *Clin Cancer Res*. 2014 Jun 15;20(12):3198-3210. doi:10.1158/1078-0432.CCR-13-3296. Epub 2014 Apr 16. Erratum in: *Clin Cancer Res*. 2017 Jan 1;23 (1):323. PMID:24740322.

© 2024 UC Regents